Greenwood Capital Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Greenwood Capital Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.14M	Buy	181,230 +832	+0.5%	+$27.7K	0.6%	59
2026 Q1	$5.43M	Sell	180,398 -142,082	-44%	-$4.57M	0.6%	54
2025 Q4	$10.1M	Sell	322,480 -47,956	-13%	-$1.18M	1.09%	19
2025 Q3	$7.48M	Buy	370,436 +56,131	+18%	+$986K	0.86%	32
2025 Q2	$5.27M	Sell	314,305 -62,726	-17%	-$1.01M	0.66%	54
2025 Q1	$5.79M	Buy	377,031 +143,506	+61%	+$2.56M	0.78%	40
2024 Q4	$5.15M	Sell	233,525 -3,240	-1%	-$58.9K	0.67%	50
2024 Q3	$4.27M	Buy	+236,765	New	+$4.14M	0.56%	60
2019 Q1	–	Sell	-42,760	Closed	-$659K	–	205
2018 Q4	$659K	Buy	42,760 +11,125	+35%	+$228K	0.17%	83
2018 Q3	$682K	Buy	+31,635	New	+$734K	0.15%	88
2017 Q4	–	Sell	-37,032	Closed	-$652K	–	236
2017 Q3	$652K	Buy	+37,032	New	+$833K	0.16%	96

Other funds holding TEVA

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

AIIMS

Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

PMG

Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return

Greenwood Capital Associates's TEVA Position: Q2 2026 in Review

Greenwood Capital Associates increased its Teva Pharmaceuticals (TEVA) stake by 0.46% in Q2 2026, buying an estimated $27.7K and bringing the position to 181,230 shares worth $6.14M. The position accounts for 0.6% of the portfolio, ranked #59.

Greenwood Capital Associates first reported a position in TEVA in Q3 2017 and has held it in 11 quarters since. The position peaked at $10.1M in Q4 2025. 246 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Greenwood Capital Associates held 181,230 shares of Teva Pharmaceuticals worth $6.14M as of Q2 2026.
Greenwood Capital Associates bought 832 Teva Pharmaceuticals shares in Q2 2026, an estimated $27.7K.
Teva Pharmaceuticals made up 0.6% of Greenwood Capital Associates's portfolio in Q2 2026, its #59 holding.
Greenwood Capital Associates first reported a position in Teva Pharmaceuticals in Q3 2017 and has held it in 11 quarters since.
Greenwood Capital Associates's Teva Pharmaceuticals position peaked at $10.1M in Q4 2025.
246 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.